Dec 9, 2024 · Adstiladrin is a prescription gene therapy used for the treatment of a certain type of bladder cancer. Adstiladrin contains nadofaragene firadenovec-vncg, a non-replicating adenovirus …

ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive …

Clinical overview Indication: ADSTILADRIN® (nadofaragene firadenovec-vncg) is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk …

Apr 1, 2025 · Abstract On December 16, 2022, the FDA approved the adenoviral vector-based gene therapy nadofaragene firadenovec-vncg (brand name Adstiladrin) for the treatment of adult patients …

Sep 12, 2023 · ADSTILADRIN ® (nadofaragene firadenovec-vncg) is the first and only FDA-approved intravesical gene therapy for the treatment of adult patients with high-risk Bacillus Calmette-Guérin …

Dec 18, 2024 · Nadofaragene Firadenovec-vncg is a non-replicating adenoviral vector-based gene therapy. The treatment delivers the human interferon alfa-2b gene, which is non-replicating, to the …

Adstiladrin is also called nadofaragene firadenovec-vncg. Adstiladrin is a gene therapy that uses a non-replicating adenoviral vector (a modified virus that cannot multiply) to deliver a gene to bladder cells. …

Aug 1, 2025 · Description Nadofaragene Firadenovec-vncg is used to treat patients with high-risk Bacillus Calmette-Guerin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with a …

Nadofaragene firadenovec uses a recombinant adenovirus that encodes for interferon alpha-2b gene. Intravesical instillation of interferon alone for bladder cancer produced complete responses that were …

Adstiladrin (nadofaragene firadenovec-vncg) is an FDA-approved gene therapy designed for high-risk BCG-unresponsive NMIBC. It represents a groundbreaking advancement in the treatment …